Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns.

Cunningham O, Scott M, Zhou ZS, Finlay WJJ

Open source

DOI
10.1080/19420862.2021.1999195
Published
2021 Jan-Dec
Container
mAbs
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/19420862.2021.1999195,
  title = {Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns.},
  author = {Cunningham O and Scott M and Zhou ZS and Finlay WJJ},
  year = {2021},
  journal = {mAbs},
  doi = {10.1080/19420862.2021.1999195},
  url = {https://doi.org/10.1080/19420862.2021.1999195}
}

RIS

TY  - JOUR
TI  - Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns.
AU  - Cunningham O
AU  - Scott M
AU  - Zhou ZS
AU  - Finlay WJJ
PY  - 2021
JO  - mAbs
DO  - 10.1080/19420862.2021.1999195
UR  - https://doi.org/10.1080/19420862.2021.1999195
ER  - 

APA

O, C., M, S., ZS, Z., & WJJ, F. (2021). Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns.. mAbs. https://doi.org/10.1080/19420862.2021.1999195

Source records